Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AAV2-BDNF | MCI due to AD (Phase 1), Alzheimer's Disease (Phase 1) | Other | DNA/RNA-based | |||
| ABBV-552 | Alzheimer's Disease (Phase 1) | AbbVie | Other | Small Molecule | ||
| ACD856 | Alzheimer's Disease (Phase 1) | AlzeCure Pharma AB | Other | Small Molecule | ||
| ADEL-Y01 | Alzheimer's Disease (Phase 1) | ADEL, Inc., Oscotec Inc. | Tau | Immunotherapy (passive) | ||
| AL044 | Alzheimer's Disease (Phase 1) | Alector | Inflammation | Immunotherapy (passive) | ||
| ALIA-1758 | Alzheimer's Disease (Phase 1) | AbbVie, Aliada Therapeutics | Amyloid-Related | Immunotherapy (passive) | ||
| ALN-APP | Alzheimer's Disease (Phase 1) | Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc. | Amyloid-Related | DNA/RNA-based | ||
| ALX-001 | BMS-984923 | Alzheimer's Disease (Phase 1) | Allyx Therapeutics, Inc. | Amyloid-Related, Other Neurotransmitters | Small Molecule | |
| ALZ-101 | Alzheimer's Disease (Phase 1) | Alzinova AB | Amyloid-Related | Immunotherapy (active) | ||
| APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
| ASN51 | ASN121151 | Alzheimer's Disease (Phase 1) | Asceneuron SA | Tau | Small Molecule | |
| AV-1959D | AV-1959 | Alzheimer's Disease (Phase 1) | Amyloid-Related | Immunotherapy (active) | ||
| AV-1980R/A | AV-1980R | Alzheimer's Disease (Phase 1) | Tau | Immunotherapy (active) | ||
| BIIB080 | IONIS-MAPTRx, ISIS 814907 |
Alzheimer's Disease (Phase 1) | Biogen, IONIS Pharmaceuticals | Tau | DNA/RNA-based | |
| BIIB113 | Alzheimer's Disease (Phase 1) | Biogen | Tau | Small Molecule | ||
| BIIB118 | PF-05251749 | Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 1) | Biogen | Other | Small Molecule | |
| CpG 1018® | CpG oligodeoxynucleotides, CpG ODN |
Alzheimer's Disease (Phase 1) | Dynavax Technologies | Amyloid-Related, Inflammation | Immunotherapy (active), DNA/RNA-based | |
| CS6253 | Cogpep™, CS-6253 |
Alzheimer's Disease (Phase 1) | Artery Therapeutics, Inc. | Amyloid-Related, Cholesterol | Small Molecule | |
| E2511 | Alzheimer's Disease (Phase 1) | Eisai Co., Ltd. | Cholinergic System | Small Molecule | ||
| Edicotinib | JNJ-40346527, JNJ-527, PRV-6527 |
Alzheimer's Disease (Phase 1) | Janssen | Inflammation | Small Molecule | |
| Efavirenz | Efavirenz | Alzheimer's Disease (Phase 1) | Amyloid-Related, Tau, Cholesterol | Small Molecule | HIV infection | |
| Empagliflozin | Jardiance, BI-10773 |
Alzheimer's Disease (Phase 1) | Boehringer Ingelheim, Eli Lilly & Co. | Other | Small Molecule | Type 2 Diabetes, Cardiovascular disease |
| Emtricitabine | Alzheimer's Disease (Phase 1) | Gilead Sciences, Inc. | Other | Small Molecule | ||
| Focused Ultrasound – Blood-Brain Barrier | FUS-BBB, MRgFUS, MRI-Guided Focused Ultrasound, FUS+MB |
Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 1), Mild Cognitive Impairment (Phase 1), Parkinson's Disease (Phase 1) | Amyloid-Related, Other | Procedural Intervention | ||
| GC021109 | Alzheimer's Disease (Phase 1) | GliaCure | Inflammation | Small Molecule | ||
| Gemfibrozil | Lopid, Jezil, Gen-Fibro |
Alzheimer's Disease (Phase 1) | Cholesterol | Small Molecule | Hyperlipidemia | |
| GSK2647544 | GSK-2647544 | Alzheimer's Disease (Phase 1) | GlaxoSmithKline (GSK) | Cholesterol | Small Molecule | |
| IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
| Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
| LX1001 | AAVrh.10-APOE2, AAVrh.10hAPOE2 |
Alzheimer's Disease (Phase 1) | Lexeo Therapeutics | Amyloid-Related | DNA/RNA-based | |
| MEDI1814 | Alzheimer's Disease (Phase 1) | AstraZeneca, Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | ||
| MemorEM Transcranial Electromagnetic Treatment | TEMT | Alzheimer's Disease (Phase 1) | NeuroEM Therapeutics, Inc. | Amyloid-Related, Other | Procedural Intervention | |
| MK-2214 | Alzheimer's Disease (Phase 1) | Merck | Tau | Immunotherapy (passive) | ||
| MK-8189 | Alzheimer's Disease (Phase 1) | Merck | Other Neurotransmitters | Small Molecule | ||
| MW151 | MW01-2-151SRM, Minozac, MW01-2-151WH, compound 17 |
Alzheimer's Disease (Phase 1) | ImmunoChem Therapeutics, LLC | Inflammation | Small Molecule | |
| NIO752 | Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1) | Novartis Pharmaceuticals Corporation | Tau | DNA/RNA-based | ||
| NTRX-07 | MDA7 | Alzheimer's Disease (Phase 1) | NeuroTherapia, Inc. | Inflammation, Other | Small Molecule | |
| OLX-07010 | Alzheimer's Disease (Phase 1) | Oligomerix, Inc. | Tau | Small Molecule | ||
| PMN310 | Alzheimer's Disease (Phase 1) | ProMIS Neurosciences, Inc. | Amyloid-Related | Immunotherapy (passive) | ||
| PRI-002 | Contraloid, contraloid acetate, RD2 |
Alzheimer's Disease (Phase 1) | Priavoid GmbH | Amyloid-Related | Small Molecule | |
| Protollin | Alzheimer's Disease (Phase 1) | I-MAB Biopharma Co., Ltd., Jiangsu Nhwa Pharmaceutical Co., Ltd | Inflammation | Immunotherapy (active) | ||
| PRX012 | Alzheimer's Disease (Phase 1) | Prothena | Amyloid-Related | Immunotherapy (passive) | ||
| S-Equol | Aus-131 | Alzheimer's Disease (Phase 1) | Ausio Pharmaceuticals, LLC | Other | Small Molecule | |
| SNP318 | Alzheimer's Disease (Phase 1) | SciNeuro Pharmaceuticals | Inflammation | Small Molecule | ||
| SUVN-G3031 | Samelisant, 17v |
Alzheimer's Disease (Phase 1) | Suven Life Sciences Ltd | Cholinergic System, Other Neurotransmitters | Small Molecule | |
| TB006 | Alzheimer's Disease (Phase 1) | TrueBinding, Inc. | Inflammation | Immunotherapy (passive) | ||
| VG-3927 | Alzheimer's Disease (Phase 1) | Vigil Neuroscience, Inc. | Amyloid-Related, Inflammation | Small Molecule | ||
| VY-TAU01 | HC3LC2, Voyager_9 |
Alzheimer's Disease (Phase 1) | Voyager Therapeutics | Tau | Immunotherapy (passive) |